2,3-Diaminopyrazines as rho kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 1137-1140

  Henderson, Alan J ^a   Hadden, Mark ^a   Guo, Cheng ^a   Douglas, Neema ^a   Decornez, Helene ^a   Hellberg, Mark R ^b   Rusinko, Andrew ^b   McLaughlin, Marsha ^b   Sharif, Naj ^b   Drace, Colene ^b   Patil, Raj ^b  

^a ALBANY MOLECULAR RESEARCH INC   (United States)

^b ALCON RESEARCH LTD   (United States)

Author keywords

Glaucoma; Intraocular pressure; IOP; Rho kinase; ROCK

Indexed keywords

2,3 DIAMINOPYRAZINE; AMINOPIPERIDINE; HN 1152; PHOSPHOTRANSFERASE; PIPERAZINE; PIPERIDINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; RHO KINASE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; ROCK1 PROTEIN, HUMAN; ROCK2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; GENE LIBRARY; GLAUCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; LOW DRUG DOSE; MICROSOME; MONKEY; NONHUMAN; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; ENZYMOLOGY; HAPLORHINI; LIVER MICROSOME; METABOLISM; RABBIT;

ANIMALS; GLAUCOMA; HAPLORHINI; HUMANS; MICROSOMES, LIVER; PROTEIN KINASE INHIBITORS; PYRAZINES; RABBITS; RHO-ASSOCIATED KINASES;

EID: 74049124256     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.12.012     Document Type: Article

References (21)

1. Breitenlechner C., Gabel M., Engh R., and Bossemeyer D. Oncol. Res. 14 (2004) 267
2. Amino M., Fukata Y., and Kaibuchi K. Exp. Cell Res. 261 (2000) 44
3. Riento K., and Ridley A.J. Nat. Rev. Mol. Cell Biol. 4 (2003) 446
4. Somlyo A.P., and Somlyo A.V. J. Physiol. 522 (2000) 177
5. Sharpe C.C., and Hendry B.M. J. Am. Soc. Nephrol. 14 (2003) 261
6. Doggrell S.A. Exp. Opin. Invest. Drugs 14 (2005) 1157
7. Aznar S., Pilar F.-V., Espina C., and Lacal J.C. Cancer Lett. 206 (2004) 181
8. Hu E., and Lee D. Exp. Opin. Ther. Targets 9 (2005) 715
9. Novak G.D. Exp. Opin. Emerg. Drugs 8 (2003) 251
10. Rao P.V., Deng P.F., Kumar J., and Epstein D.L. Invest. Ophthalmol. Vis. Sci. 42 (2001) 1029
11. Tanihara H., Inatani M., Honjo M., Tokushige H., Azuma J., and Araie M. Arch. Ophthalmol. 126 (2008) 309
12. Vitse O., Laurent F., Pocock T.M., Benezech V., Zamik L., Elliott K.R., Subra G., Portet K., Bompart J., Chapat J.P., Sunall R.C., Michel A., and Bonnet P.A. Bioorg. Med. Chem. 7 (1999) 1059
13. Miyaura N., and Suzuki A. J. Chem. Soc., Chem. Commun. (1979) 866
14. Milstein D., and Stille J.K. J. Am. Chem. Soc. 100 (1978) 3636
15. Jiang B., Cai-guang Y., Wen-Nan X., and Wang J. Bioorg. Med. Chem. 9 (2001) 1149
16. -3, units per well. Enzyme reaction was allowed to proceed for 60 min at 23 °C (well volume of 20 μL) then 60 μL of the binding solution (IMAP kit provided by Molecular Devices, Sunnyvale, CA) added to each well, and incubated for a further 30 min at 23 °C. Reaction mixtures were then analyzed by fluorescence polarization.
17. Hellberg M.R., Sallee V.L., McLaughlin M.A., Sharif N.A., Desantis L., Dean T.R., and Zinke P.W. J. Ocul. Pharmacol. Ther. 5 (2001) 421
18. HN1152 (also known as H-1152 or dimethyl-fasudil) has the structure shown below.{A figure is presented}
19. The seven cytochrome P450's tested were 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4.
20. The percentage of parent compound remaining after 1 h was determined by incubation with human liver microsomes for 60 min. The reported result is a mean of two separate analyses performed in duplicate.
21. Tokushie H., Inatani M., Nemoto S., Sakai H., Katayama K., Uehata M., and Tanihata H. Invest. Ophthalmol. Vis. Sci. 48 (2007) 3216